Tandem Diabetes Care Inc (TNDM) Receives Consensus Rating of “Hold” from Analysts

Tandem Diabetes Care Inc (NASDAQ:TNDM) has earned a consensus rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $11.30.

Several brokerages have weighed in on TNDM. Zacks Investment Research cut shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating in a research note on Friday. Oppenheimer reissued a “buy” rating on shares of Tandem Diabetes Care in a research note on Thursday. Robert W. Baird raised shares of Tandem Diabetes Care from a “neutral” rating to an “outperform” rating in a research note on Friday. ValuEngine cut shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Finally, Cowen reissued a “hold” rating on shares of Tandem Diabetes Care in a research note on Tuesday, February 27th.

How to Become a New Pot Stock Millionaire

In related news, CEO Kim D. Blickenstaff purchased 750,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $2.00 per share, with a total value of $1,500,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher J. Twomey purchased 75,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $150,000.00. The disclosure for this purchase can be found here. Insiders have bought 850,539 shares of company stock worth $1,749,091 over the last three months. 20.90% of the stock is owned by insiders.

A hedge fund recently raised its stake in Tandem Diabetes Care stock. Russell Investments Group Ltd. boosted its holdings in Tandem Diabetes Care Inc (NASDAQ:TNDM) by 13.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 659,993 shares of the medical device company’s stock after buying an additional 78,748 shares during the period. Russell Investments Group Ltd. owned approximately 6.52% of Tandem Diabetes Care worth $482,000 as of its most recent SEC filing. 8.74% of the stock is currently owned by institutional investors and hedge funds.

Shares of TNDM stock opened at $3.99 on Friday. The company has a debt-to-equity ratio of -2.63, a current ratio of 1.78 and a quick ratio of 1.03. Tandem Diabetes Care has a 52 week low of $2.14 and a 52 week high of $13.00.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, March 1st. The medical device company reported ($1.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.13). The business had revenue of $40.00 million for the quarter, compared to analysts’ expectations of $38.41 million. The company’s revenue was up 61.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.48) earnings per share. analysts forecast that Tandem Diabetes Care will post -1.41 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Tandem Diabetes Care Inc (TNDM) Receives Consensus Rating of “Hold” from Analysts” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3295751/tandem-diabetes-care-inc-tndm-receives-consensus-rating-of-hold-from-analysts.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

3D Systems  Shares Sold by Deutsche Bank AG
3D Systems Shares Sold by Deutsche Bank AG
Bluerock Residential  Shares Bought by Deutsche Bank AG
Bluerock Residential Shares Bought by Deutsche Bank AG
Deltec Asset Management LLC Has $15.67 Million Position in Facebook, Inc.
Deltec Asset Management LLC Has $15.67 Million Position in Facebook, Inc.
Insider Selling: New York Times Co  Insider Sells $2,295,000.00 in Stock
Insider Selling: New York Times Co Insider Sells $2,295,000.00 in Stock
Cowen Prime Services LLC Acquires 570 Shares of ExxonMobil
Cowen Prime Services LLC Acquires 570 Shares of ExxonMobil
Financial Comparison: SPX  versus Lincoln Electric
Financial Comparison: SPX versus Lincoln Electric


© 2006-2018 Ticker Report. Google+.